Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma

Sigurdur Y. Kristinsson, Thomas R. Fears, Gloria Gridley, Ingemar Turesson, Ulf Henrik Mellqvist, Magnus Björkholm, Ola Landgren

Research output: Contribution to journalArticlepeer-review

129 Scopus citations


Patients with multiple myeloma (MM) have an increased risk of deep venous thrombosis (DVT), particularly when treated with immunomodulatory drugs. Recently, 2 small hospital-based studies observed persons with the MM precursor condition, monoclonal gammopathy of undetermined significance (MGUS), to be at increased risk of developing DVT. Among 4 196 197 veterans hospitalized at least once at US Veterans Affairs hospitals, we identified a total of 2374 cases of MGUS, and 39 272 persons were diagnosed with DVT (crude incidence 0.9 per 1000 person-years). A total of 31 and 151 DVTs occurred among MQUS and MM patients, respectively (crude incidence 3.1 and 8.7 per 1000 person-years, respectively; P < .01). Compared with the entire study population, the relative risk (RR) of DVT after a diagnosis of MGUS and MM was 3.3 (95% confidence interval [Cl], 2.3-4.7) and 9.2 (95% Cl, 7.9-10.8), respectively. The most prominent excess risk of DVT was found during the first year after diagnosis of MGUS (RR = 8.4; 95% Cl, 5.7-12.2) and MM (RR = 11.6; 95% Cl, 9.2-14.5). Among 229 MGUS cases (9.5%) that progressed to MM, only one person had a DVT diagnosis before transformation. Our findings suggest the operation of shared underlying mechanisms causing coagulation abnormalities among patients with MGUS and MM.

Original languageEnglish (US)
Pages (from-to)3582-3586
Number of pages5
Issue number9
StatePublished - Nov 1 2008
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma'. Together they form a unique fingerprint.

Cite this